GlassScriptPhysician profile
Kimberly Rayborn
NPI 1578733986
$2,967.85
in general payments reported to CMS, 2019-2025
28 companies · $723 in 2025
The $723 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $513 · 2022: $369 · 2023: $770 · 2024: $592 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $321.90 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $256.79 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $193.21 | 2022-2025 | Wegovy |
| Glaxosmithkline, LLC. | $164.46 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $147.09 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $146.61 | 2023-2025 | |
| Corcept Therapeutics | $107.23 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $94.92 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.53 | 2021-2023 | Belsomra, Segluromet, Steglatro |
| Pfizer INC. | $73.19 | 2023-2024 | |
| Amarin Pharma, INC. | $71.92 | 2021 | |
| Exact Sciences Corporation | $71.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ucb, INC. | $60.78 | 2022 | |
| Esperion Therapeutics, INC. | $58.83 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $58.54 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $38.47 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $29.47 | 2024-2025 | Nuzyra |
| Amgen INC. | $27.92 | 2024-2025 | Otezla, Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $27.08 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $21.11 | 2021 | |
| Nestle Healthcare Nutrition INC. | $20.49 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.49 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $15.59 | 2025 | Onzetra Xsail, Contrave |
| Sanofi-Aventis U.S. LLC | $15.54 | 2023 | |
| Antares Pharma, INC. | $14.31 | 2022 | |
| Astellas Pharma US INC | $13.78 | 2021 | |
| Genentech USA, INC. | $7.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Rayborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.